SQSTM1 and early-onset autosomal dominant Alzheimer disease: In addition, considering that p62 is included in the neurodegenerative disease-related aggregates, such as Levy’s body, Huntington’s aggregate, and in the neurofibrillary degeneration in Alzheimer’s disease, targeting the p62-related aggregates may be effective for the treatment of neurodegenerative diseases [19–23].